VG-201

N/A

Report date: 2026/04/06 20:01:48

Base Information

Drug NameVG-201
Drug Alias Name重组人IL12/15单纯疱疹I型双调控溶瘤病毒注射液(Vero细胞)VG-201
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionInterleukin-12 stimulantsInterleukin-15 stimulantsInterleukin-15 receptor subunit alpha stimulants
TargetsInterleukin-12Interleukin-15Interleukin-15 receptor subunit alpha
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesViroGin Biotech Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAkeso-Sino Pharma Co LtdShanghai Funuojian Biotechnology Co LtdViroGin Biotech Ltd +[4] 
Inactive CompaniesVirogin Biotech (Shenzhen) LtdFenojian Biotechnology (Nantong) Co Ltd
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A